ZA200601214B - Composition and method for facilitating bone healing - Google Patents

Composition and method for facilitating bone healing Download PDF

Info

Publication number: ZA200601214B
Authority: ZA; South Africa
Prior art keywords: vitamin; nutritional composition; lysine; proline; acid
Prior art date: 2003-09-05

Application number

ZA200601214A

Other languages

English (en)

Inventor

Rath Matthias

Netke Shrirang

Waheed M Roomi

Ivanov Vadim

Niedzwiecki Aleksandra

Original Assignee

Rath Matthias

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-05

Filing date

2004-06-24

Publication date

2007-04-25

2004-06-24 Application filed by Rath Matthias filed Critical Rath Matthias

2007-04-25 Publication of ZA200601214B publication Critical patent/ZA200601214B/en

Links

230000035876 healing Effects 0.000 title claims description 75
239000000203 mixture Substances 0.000 title claims description 72
210000000988 bone and bone Anatomy 0.000 title claims description 52
238000000034 method Methods 0.000 title abstract description 14
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 92
235000010323 ascorbic acid Nutrition 0.000 claims abstract description 43
239000011668 ascorbic acid Substances 0.000 claims abstract description 43
229960005070 ascorbic acid Drugs 0.000 claims abstract description 41
239000004472 Lysine Substances 0.000 claims abstract description 40
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 37
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 36
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 34
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 29
239000010949 copper Substances 0.000 claims abstract description 29
229910052802 copper Inorganic materials 0.000 claims abstract description 29
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 26
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 26
239000011777 magnesium Substances 0.000 claims abstract description 26
229910052749 magnesium Inorganic materials 0.000 claims abstract description 26
239000004475 Arginine Substances 0.000 claims abstract description 23
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 23
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 23
229910052711 selenium Inorganic materials 0.000 claims abstract description 23
239000011669 selenium Substances 0.000 claims abstract description 23
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 17
229940108928 copper Drugs 0.000 claims abstract description 5
239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
229940088594 vitamin Drugs 0.000 claims description 74
229930003231 vitamin Natural products 0.000 claims description 74
235000013343 vitamin Nutrition 0.000 claims description 74
239000011782 vitamin Substances 0.000 claims description 74
150000003722 vitamin derivatives Chemical class 0.000 claims description 73
235000016709 nutrition Nutrition 0.000 claims description 63
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 53
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 45
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 40
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 40
229910052791 calcium Inorganic materials 0.000 claims description 34
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 33
239000011575 calcium Substances 0.000 claims description 33
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 25
239000011701 zinc Substances 0.000 claims description 25
229910052725 zinc Inorganic materials 0.000 claims description 25
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 24
229910052804 chromium Inorganic materials 0.000 claims description 24
239000011651 chromium Substances 0.000 claims description 24
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 24
235000019155 vitamin A Nutrition 0.000 claims description 24
239000011719 vitamin A Substances 0.000 claims description 24
239000011713 pantothenic acid Substances 0.000 claims description 23
235000019161 pantothenic acid Nutrition 0.000 claims description 23
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 22
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 22
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 22
235000020971 citrus fruits Nutrition 0.000 claims description 22
229920002770 condensed tannin Polymers 0.000 claims description 22
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 22
235000018417 cysteine Nutrition 0.000 claims description 22
229960000304 folic acid Drugs 0.000 claims description 22
235000019152 folic acid Nutrition 0.000 claims description 22
239000011724 folic acid Substances 0.000 claims description 22
229960003512 nicotinic acid Drugs 0.000 claims description 22
235000001968 nicotinic acid Nutrition 0.000 claims description 22
239000011664 nicotinic acid Substances 0.000 claims description 22
229940055726 pantothenic acid Drugs 0.000 claims description 22
235000018192 pine bark supplement Nutrition 0.000 claims description 22
229940106796 pycnogenol Drugs 0.000 claims description 22
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 21
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 21
ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 21
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 21
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 21
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 21
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 21
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 21
229960000367 inositol Drugs 0.000 claims description 21
229910052750 molybdenum Inorganic materials 0.000 claims description 21
239000011733 molybdenum Substances 0.000 claims description 21
239000011574 phosphorus Substances 0.000 claims description 21
229910052698 phosphorus Inorganic materials 0.000 claims description 21
229910052700 potassium Inorganic materials 0.000 claims description 21
239000011591 potassium Substances 0.000 claims description 21
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 21
229940045997 vitamin a Drugs 0.000 claims description 21
241000282414 Homo sapiens Species 0.000 claims description 20
229930003427 Vitamin E Natural products 0.000 claims description 20
229960002685 biotin Drugs 0.000 claims description 20
239000011616 biotin Substances 0.000 claims description 20
235000020958 biotin Nutrition 0.000 claims description 20
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 20
235000019165 vitamin E Nutrition 0.000 claims description 20
239000011709 vitamin E Substances 0.000 claims description 20
229940046009 vitamin E Drugs 0.000 claims description 20
229930003270 Vitamin B Natural products 0.000 claims description 18
235000019156 vitamin B Nutrition 0.000 claims description 18
239000011720 vitamin B Substances 0.000 claims description 18
PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 15
229960004203 carnitine Drugs 0.000 claims description 15
241000124008 Mammalia Species 0.000 claims description 10
230000037396 body weight Effects 0.000 claims description 10
UIXPTCZPFCVOQF-UHFFFAOYSA-N ubiquinone-0 Chemical compound COC1=C(OC)C(=O)C(C)=CC1=O UIXPTCZPFCVOQF-UHFFFAOYSA-N 0.000 claims description 10
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
229960005069 calcium Drugs 0.000 claims description 5
229960003646 lysine Drugs 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
229960002429 proline Drugs 0.000 claims description 4
235000019166 vitamin D Nutrition 0.000 claims description 4
239000011710 vitamin D Substances 0.000 claims description 4
229960003121 arginine Drugs 0.000 claims description 3
229960002433 cysteine Drugs 0.000 claims description 3
235000005282 vitamin D3 Nutrition 0.000 claims description 3
239000011647 vitamin D3 Substances 0.000 claims description 3
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
229940021056 vitamin d3 Drugs 0.000 claims description 3
229930003316 Vitamin D Natural products 0.000 claims 3
150000003710 vitamin D derivatives Chemical class 0.000 claims 3
229940046008 vitamin d Drugs 0.000 claims 3
239000003085 diluting agent Substances 0.000 abstract description 4
239000000546 pharmaceutical excipient Substances 0.000 abstract description 4
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 3
229930003268 Vitamin C Natural products 0.000 abstract description 3
235000019154 vitamin C Nutrition 0.000 abstract description 3
239000011718 vitamin C Substances 0.000 abstract description 3
229940094952 green tea extract Drugs 0.000 abstract 2
235000020688 green tea extract Nutrition 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 1
229960004308 acetylcysteine Drugs 0.000 abstract 1
229940091250 magnesium supplement Drugs 0.000 abstract 1
239000011572 manganese Substances 0.000 abstract 1
229910052748 manganese Inorganic materials 0.000 abstract 1
229940091258 selenium supplement Drugs 0.000 abstract 1
208000010392 Bone Fractures Diseases 0.000 description 38
235000018977 lysine Nutrition 0.000 description 27
206010017076 Fracture Diseases 0.000 description 24
235000013930 proline Nutrition 0.000 description 24
239000000902 placebo Substances 0.000 description 20
229940068196 placebo Drugs 0.000 description 20
239000003826 tablet Substances 0.000 description 17
235000009697 arginine Nutrition 0.000 description 15
102000008186 Collagen Human genes 0.000 description 11
108010035532 Collagen Proteins 0.000 description 11
239000005515 coenzyme Substances 0.000 description 11
229920001436 collagen Polymers 0.000 description 11
230000009467 reduction Effects 0.000 description 10
239000004615 ingredient Substances 0.000 description 9
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000002253 acid Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000009826 distribution Methods 0.000 description 5
238000005303 weighing Methods 0.000 description 5
206010020649 Hyperkeratosis Diseases 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
235000015097 nutrients Nutrition 0.000 description 4
210000000963 osteoblast Anatomy 0.000 description 4
230000008569 process Effects 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
235000019766 L-Lysine Nutrition 0.000 description 3
208000004367 Tibial Fractures Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
210000003414 extremity Anatomy 0.000 description 3
238000009472 formulation Methods 0.000 description 3
208000014674 injury Diseases 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
239000011707 mineral Substances 0.000 description 3
235000010755 mineral Nutrition 0.000 description 3
230000008439 repair process Effects 0.000 description 3
230000009469 supplementation Effects 0.000 description 3
239000011573 trace mineral Substances 0.000 description 3
235000013619 trace mineral Nutrition 0.000 description 3
230000002485 urinary effect Effects 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 2
102000015427 Angiotensins Human genes 0.000 description 2
108010064733 Angiotensins Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
208000002565 Open Fractures Diseases 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000013459 approach Methods 0.000 description 2
229940072107 ascorbate Drugs 0.000 description 2
235000010385 ascorbyl palmitate Nutrition 0.000 description 2
230000033558 biomineral tissue development Effects 0.000 description 2
230000037118 bone strength Effects 0.000 description 2
235000010376 calcium ascorbate Nutrition 0.000 description 2
229940047036 calcium ascorbate Drugs 0.000 description 2
239000011692 calcium ascorbate Substances 0.000 description 2
BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
210000000845 cartilage Anatomy 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
210000001612 chondrocyte Anatomy 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 description 2
RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000008021 deposition Effects 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
239000000835 fiber Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
210000003127 knee Anatomy 0.000 description 2
229940074358 magnesium ascorbate Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 2
WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
-1 nolybdenum Chemical compound 0.000 description 2
230000011164 ossification Effects 0.000 description 2
230000036407 pain Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000011505 plaster Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000013589 supplement Substances 0.000 description 2
229910052718 tin Inorganic materials 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
RIPZAYPXOPSKEE-DKWTVANSSA-N (2r)-2-amino-3-sulfanylpropanoic acid;hydrate Chemical compound O.SC[C@H](N)C(O)=O RIPZAYPXOPSKEE-DKWTVANSSA-N 0.000 description 1
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
239000005749 Copper compound Substances 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
206010018852 Haematoma Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001024304 Mino Species 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 1
108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000000274 adsorptive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000000578 anorexic effect Effects 0.000 description 1
210000000544 articulatio talocruralis Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037182 bone density Effects 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
230000018678 bone mineralization Effects 0.000 description 1
230000010072 bone remodeling Effects 0.000 description 1
210000003364 bony callus Anatomy 0.000 description 1
230000002308 calcification Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000002648 chondrogenic effect Effects 0.000 description 1
WTEVQBCEXWBHNA-JXMROGBWSA-N citral A Natural products CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
150000001880 copper compounds Chemical class 0.000 description 1
229960002104 cyanocobalamin Drugs 0.000 description 1
235000000639 cyanocobalamin Nutrition 0.000 description 1
239000011666 cyanocobalamin Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000008571 general function Effects 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
210000004394 hip joint Anatomy 0.000 description 1
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
210000003559 hypertrophic chondrocyte Anatomy 0.000 description 1
230000003116 impacting effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
210000000629 knee joint Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000009196 low level laser therapy Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
150000003147 proline derivatives Chemical class 0.000 description 1
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
239000011764 pyridoxine hydrochloride Substances 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229960002718 selenomethionine Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960004860 thiamine mononitrate Drugs 0.000 description 1
235000019191 thiamine mononitrate Nutrition 0.000 description 1
239000011748 thiamine mononitrate Substances 0.000 description 1
UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
239000011135 tin Substances 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000008733 trauma Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
229940071566 zinc glycinate Drugs 0.000 description 1
UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Natural Medicines & Medicinal Plants (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Medical Informatics (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Physical Education & Sports Medicine (AREA)
Nutrition Science (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Botany (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

ZA200601214A 2003-09-05 2004-06-24 Composition and method for facilitating bone healing ZA200601214B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/657,019 US20050053673A1 (en)	2003-09-05	2003-09-05	Composition and method for facilitating bone healing

Publications (1)

Publication Number	Publication Date
ZA200601214B true ZA200601214B (en)	2007-04-25

Family

ID=34226477

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ZA200601214A ZA200601214B (en)	2003-09-05	2004-06-24	Composition and method for facilitating bone healing
ZA200407064A ZA200407064B (en)	2003-09-05	2004-09-03	Pharmaceutical composition and method for retardation of the progression of atherosclerosis.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ZA200407064A ZA200407064B (en)	2003-09-05	2004-09-03	Pharmaceutical composition and method for retardation of the progression of atherosclerosis.

Country Status (20)

Country	Link
US (4)	US20050053673A1 (pt)
EP (1)	EP1662908B9 (pt)
JP (1)	JP2007504182A (pt)
KR (1)	KR20060069851A (pt)
CN (2)	CN1845683A (pt)
AT (1)	ATE458478T1 (pt)
AU (1)	AU2004269867A1 (pt)
BR (1)	BRPI0414076A (pt)
CA (1)	CA2532941A1 (pt)
DE (2)	DE602004022060D1 (pt)
ES (2)	ES2330111T3 (pt)
IL (2)	IL173159A0 (pt)
MX (1)	MXPA06002526A (pt)
NO (2)	NO20061461L (pt)
PL (1)	PL1662908T3 (pt)
RS (2)	RS20060150A (pt)
RU (1)	RU2006110949A (pt)
UA (1)	UA81973C2 (pt)
WO (2)	WO2005023020A1 (pt)
ZA (2)	ZA200601214B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050130321A1 (en) *	2001-04-23	2005-06-16	Nicholson Jeremy K.	Methods for analysis of spectral data and their applications
US8377904B2 (en)	2004-02-09	2013-02-19	Hill's Pet Nutrition, Inc.	Composition and method for use in cartilage affecting conditions
DE602006015665D1 (de) *	2005-10-06	2010-09-02	Nestec Sa	Probiotische enterokokken für eine verbesserte immunität
EP1862163A1 (de) *	2006-05-12	2007-12-05	Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG	L-Carnitin zur Kristallisationsverzögerung
US20080031869A1 (en) *	2006-08-02	2008-02-07	Fontaine Juliette S	Pain relief composition
WO2008139314A1 (en) *	2007-05-11	2008-11-20	Horphag Research (Luxembourg) Holding Sa	Compositions and methods for treating joint disorders
US20090060879A1 (en) *	2007-09-04	2009-03-05	The Procter & Gamble Company	Oral Compositions, Products and Methods Of Use
US8466187B2 (en)	2007-09-18	2013-06-18	Thermolife International, Llc	Amino acid compositions
CN101925357B (zh) *	2008-01-28	2012-12-12	珍明珠集团有限公司	含有钙、镁、锌和维生素d3并能预防和改善骨质疏松症的组合物
IT1397522B1 (it) *	2009-12-21	2013-01-16	Solartium Entpr Ltd	Uso di una combinazione per il trattamento dell'osteoartrosi
BE1019135A5 (nl) *	2010-01-08	2012-03-06	Lab Smeets Nv	Voedingssupplement bevattende glucosamine.
EP2648717A1 (en) *	2010-12-09	2013-10-16	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.	Composition for topical use for treating skin disorders
AU2012242565B2 (en)	2011-04-13	2017-05-11	Thermolife International, Llc	N-Acetyl Beta Alanine methods of use
WO2013108263A1 (en)	2012-01-18	2013-07-25	Zota Health Care Ltd	Pharmaceutical formulation to reduce inflammation of bones and joint friction with improved cartilage quality
US20160081959A1 (en) *	2014-09-24	2016-03-24	Glanbia Plc	Method of using arginine silicate inositol complex for wound healing or repair
JP6211558B2 (ja) *	2015-05-14	2017-10-11	株式会社東洋新薬	美容組成物
JP6608874B2 (ja) *	2017-06-15	2019-11-20	株式会社東洋新薬	美容組成物
JP6906248B2 (ja) *	2017-06-15	2021-07-21	株式会社東洋新薬	美容組成物
US10004757B1 (en)	2017-09-22	2018-06-26	Nutri Vida, LLC	Oral supplement
US20190175533A1 (en) *	2017-12-12	2019-06-13	Pharmco International Inc.	Nutritional supplement for improved calcium absorption
JP7098198B2 (ja) *	2019-10-08	2022-07-11	株式会社東洋新薬	美容組成物
IT202000009700A1 (it) *	2020-05-04	2021-11-04	Parthenogen Sagl	Combinazione di micronutrienti per stimolare la produzione endogena di sulfide di idrogeno (h2s)
CN111529709A (zh) *	2020-06-03	2020-08-14	北京易思腾翻译服务有限公司	一种可用于体重控制且可逆转动脉粥样硬化的组合物
US12156886B2 (en)	2020-11-12	2024-12-03	Thermolife International, Llc	Methods of increasing blood oxygen saturation
US11865139B2 (en)	2020-11-12	2024-01-09	Thermolife International, Llc	Method of treating migraines and headaches
MX2023009015A (es)	2021-02-11	2023-08-08	Thermolife Int Llc	Un metodo para administrar gas de oxido nitrico.
CN117412776A (zh) *	2021-06-03	2024-01-16	美格乐·凯默斯崴德公司	用于mRNA递送的药学上可接受的含水凝胶组合物
US20230293618A1 (en) *	2022-02-11	2023-09-21	Jessica Karns	Compositions comprising orange peel derivatives and dicalcium phosphate and methods of using
CN114560924B (zh) *	2022-02-21	2023-06-20	华南理工大学	一种促进成骨细胞分化的含硒特立帕肽和融合多肽及其应用
US12029726B1 (en) *	2023-07-06	2024-07-09	Matthias W. Rath	Composition and method of treating conditions associated with extracellular matrix dysfunction by administering micronutrient composition
WO2026073932A1 (en) *	2024-10-01	2026-04-09	Société des Produits Nestlé S.A.	Compositions containing vitamin b6 and nicotinamide and methods of using such compositions for use in promoting bone growth

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3405120A (en) *	1966-01-27	1968-10-08	Green Cross Corp	Low molecular chondroitin sulfate and method for manufacturing the same
SU1268169A1 (ru) *	1979-12-17	1986-11-07	Актюбинский государственный медицинский институт	Способ лечени переломов костей
US4968719A (en) *	1989-04-03	1990-11-06	Sigma Tau, Industrie Farmaceutiche Riunite Spa	Method for treating vascular disease
US5232709A (en) *	1990-08-06	1993-08-03	The Procter & Gamble Company	Calcium and trace mineral supplements comprising estrogen
US5968983A (en) *	1994-10-05	1999-10-19	Nitrosystems, Inc	Method and formulation for treating vascular disease
US6440446B1 (en) *	1998-04-22	2002-08-27	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Agent for anti-osteoporosis
JP2000063284A (ja) *	1998-08-21	2000-02-29	Terumo Corp	炎症性腸疾患再燃防止剤
US6914073B2 (en) *	1999-03-18	2005-07-05	Bristol Myers Squibb Company	Vitamin formulation for cardiovascular health
US6528042B1 (en) *	1999-10-08	2003-03-04	Galileo Laboratories, Inc.	Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7235237B2 (en) *	1999-10-29	2007-06-26	Nitromed, Inc.	Methods of treating vascular diseases characterized by nitric oxide insufficiency
GB0009056D0 (en) *	2000-04-12	2000-05-31	Nestle Sa	Composition comprising free amino acids
US6579544B1 (en) *	2000-05-31	2003-06-17	Nutriex, L.L.C.	Method for supplementing the diet
UA77660C2 (en) *	2000-10-03	2007-01-15		Compositions and methods for reducing plasma lipoprotein a level in human
DE60028376T2 (de) *	2000-10-09	2007-06-06	Rath, Matthias, Dr.	Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses
JP2003061631A (ja) *	2001-08-28	2003-03-04	Takaaki Morikawa	クエン酸とアミノ酸を主成分とした粉末飲料及び食品。
DE20207569U1 (de) *	2002-05-14	2002-12-05	Kyberg Pharma Vertriebs-GmbH & Co. KG, 82041 Oberhaching	Diätetische und pharmazeutische Zusammensetzungen
US6551629B1 (en) *	2002-07-03	2003-04-22	Vitacost.Com, Inc.	Cardiovascular promotion and maintenance composition
CN1234371C (zh) *	2003-01-28	2006-01-04	马驷	纳米铜粉作为制备预防治疗骨质疏松、骨折药物的应用

2003
- 2003-09-05 US US10/657,019 patent/US20050053673A1/en not_active Abandoned
2004
- 2004-03-15 US US10/801,262 patent/US20050053674A1/en not_active Abandoned
- 2004-06-24 BR BRPI0414076-1A patent/BRPI0414076A/pt not_active IP Right Cessation
- 2004-06-24 PL PL04740254T patent/PL1662908T3/pl unknown
- 2004-06-24 CN CNA200480025244XA patent/CN1845683A/zh active Pending
- 2004-06-24 RS YUP-2006/0150A patent/RS20060150A/sr unknown
- 2004-06-24 JP JP2006525052A patent/JP2007504182A/ja active Pending
- 2004-06-24 US US10/570,735 patent/US20070122399A1/en not_active Abandoned
- 2004-06-24 MX MXPA06002526A patent/MXPA06002526A/es not_active Application Discontinuation
- 2004-06-24 WO PCT/EP2004/006841 patent/WO2005023020A1/en not_active Ceased
- 2004-06-24 CA CA002532941A patent/CA2532941A1/en not_active Abandoned
- 2004-06-24 EP EP04740254A patent/EP1662908B9/en not_active Expired - Lifetime
- 2004-06-24 UA UAA200603750A patent/UA81973C2/uk unknown
- 2004-06-24 ZA ZA200601214A patent/ZA200601214B/en unknown
- 2004-06-24 KR KR1020067003910A patent/KR20060069851A/ko not_active Ceased
- 2004-06-24 RU RU2006110949/13A patent/RU2006110949A/ru not_active Application Discontinuation
- 2004-06-24 DE DE602004022060T patent/DE602004022060D1/de not_active Expired - Lifetime
- 2004-06-24 AU AU2004269867A patent/AU2004269867A1/en not_active Abandoned
- 2004-06-24 ES ES04740254T patent/ES2330111T3/es not_active Expired - Lifetime
- 2004-08-18 US US10/570,733 patent/US20070166400A1/en not_active Abandoned
- 2004-08-18 CN CNA2004800252581A patent/CN1845729A/zh active Pending
- 2004-08-18 ES ES04764249T patent/ES2341717T3/es not_active Expired - Lifetime
- 2004-08-18 RS YUP-2006/0149A patent/RS20060149A/sr unknown
- 2004-08-18 AT AT04764249T patent/ATE458478T1/de active
- 2004-08-18 DE DE602004025728T patent/DE602004025728D1/de not_active Expired - Lifetime
- 2004-09-02 WO PCT/US2004/028519 patent/WO2005025589A1/en not_active Ceased
- 2004-09-03 ZA ZA200407064A patent/ZA200407064B/xx unknown
2006
- 2006-01-15 IL IL173159A patent/IL173159A0/en unknown
- 2006-01-19 IL IL173257A patent/IL173257A0/en unknown
- 2006-03-31 NO NO20061461A patent/NO20061461L/no not_active Application Discontinuation
- 2006-04-04 NO NO20061532A patent/NO20061532L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1845729A (zh)	2006-10-11
NO20061532L (no)	2006-04-04
US20050053674A1 (en)	2005-03-10
RS20060150A (sr)	2007-12-31
WO2005025589A1 (en)	2005-03-24
AU2004269867A1 (en)	2005-03-17
CN1845683A (zh)	2006-10-11
NO20061461L (no)	2006-03-31
US20070166400A1 (en)	2007-07-19
ES2330111T3 (es)	2009-12-04
MXPA06002526A (es)	2006-06-20
WO2005023020A1 (en)	2005-03-17
JP2007504182A (ja)	2007-03-01
US20050053673A1 (en)	2005-03-10
EP1662908B1 (en)	2009-07-15
RS20060149A (sr)	2008-04-04
EP1662908A1 (en)	2006-06-07
US20070122399A1 (en)	2007-05-31
DE602004025728D1 (de)	2010-04-08
IL173257A0 (en)	2006-06-11
ZA200407064B (en)	2005-05-11
BRPI0414076A (pt)	2006-10-24
KR20060069851A (ko)	2006-06-22
EP1662908B9 (en)	2010-09-01
CA2532941A1 (en)	2005-03-17
IL173159A0 (en)	2006-06-11
PL1662908T3 (pl)	2009-12-31
ATE458478T1 (de)	2010-03-15
DE602004022060D1 (de)	2009-08-27
ES2341717T3 (es)	2010-06-25
UA81973C2 (uk)	2008-02-25
RU2006110949A (ru)	2007-10-10

Publication	Publication Date	Title
EP1662908B9 (en)	2010-09-01	Composition and method for facilitating bone healing
TWI457079B (zh)	2014-10-21	複維生素及礦物質補充劑
US20030190369A1 (en)	2003-10-09	Vitamin formulation for enhancing bone strength
US20070160591A1 (en)	2007-07-12	Peri-operative and peri-procedure nutritional supplementation
US6790462B2 (en)	2004-09-14	Calcium dietary supplement
EP1083915B1 (en)	2007-02-28	Compositions comprising molybdenum for enhancing protein anabolism and detoxification
JP2011510922A (ja)	2011-04-07	骨粗鬆症の予防及び回復のためのカルシウム、マグネシウム、亜鉛、ビタミンｄ３を含む調剤
WO2004017916A2 (en)	2004-03-04	Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition
EP3009133B1 (en)	2016-10-05	Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patient which have been subjected to gastric bypass-surgery
CA3057760A1 (en)	2018-10-04	Physiologically active composition
RU2379043C2 (ru)	2010-01-20	Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы
US20030096018A1 (en)	2003-05-22	Multi-vitamin and hormone replacement supplement
EA000677B1 (ru)	2000-02-28	Способ предотвращения остеопороза
US20030045510A1 (en)	2003-03-06	Estrogen-plus
CA2159355C (en)	2006-12-12	Method and composition for treatment of osteoporosis
TW201105333A (en)	2011-02-16	Agent for preventing non-traumatic vertebral fracture in severe osteoporosis patients which comprises eldecalcitol
AU5778801A (en)	2002-02-21	Improvements in effervescent tablet manufacture
AU694112B2 (en)	1998-07-16	Method and composition for treatment of osteoporosis
Galesanu et al.	2016	ATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOS-PHONATES THERAPY: CASE REPORT
WO2026047691A1 (en)	2026-03-05	Synergistic nutraceutical composition to improve calcium absorption
Prescott	1997	Alendronic acid: benefits in prevention and treatment of PMO
CN103585174A (zh)	2014-02-19	用于预防或治疗骨和关节疾病的组合物及制备方法及应用